Johnson & Johnson extends tender offer for Omrix

By Lisa Kerner

Charlotte, N.C., Dec. 19 - Johnson & Johnson extended its previously announced cash tender offer for Omrix Biopharmaceuticals, Inc. to midnight ET on Dec. 26 from Dec. 23, it was announced on Friday.

About 4,101,234 shares of Omrix common stock had been validly tendered and not withdrawn, including roughly 2,000 shares subject to guaranteed delivery procedures, as of 3 p.m. on Dec. 19, according to a Johnson & Johnson.

Binder Merger Sub, Inc., a Johnson & Johnson subsidiary, began the $25-per-share cash tender offer for Omrix on Nov. 25.

Johnson & Johnson, a New Brunswick, N.J.-based pharmaceutical company, agreed to acquire Omrix for $438 million.

Omrix, a New York-based biopharmaceutical company, will operate as a standalone entity through Johnson & Johnson's Ethicon, Inc., which provides suture, mesh, hemostats and other products for surgical procedures, it was previously reported.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.